Term
Ropinirole HCl
Brand Name |
|
Definition
|
|
Term
Ropinirole HCl
Dosage Forms |
|
Definition
Tablets: 0.25, 0.5, 1, 2, 3, 4, and 5 mg
Tablets ER (Requip XL): 2, 3, 4, and 8 mg |
|
|
Term
Ropinirole HCl
FDA indications/Dosages |
|
Definition
1. Idiopathic Parkinson's disease
Recommended starting dose: 0.25 mg TID
Weekly dosage increments: 0.25 mg/dose (TID)
Gradual tapering max: 24 mg/day
Normal dose range: 0.5-5 mg TID
To DC: decrease dose frequency to BID x 4 days then QD x 3 days before stopping
2. Moderate-severe primary Restless Legs Syndrome
Recommended starting dose: 0.25 QD, 1-3 hour before bedtime
Dosage increased to 0.5 mg after 2 days, & to 1 mg QD at the end of the 1st week
Weekly dosage increments: 0.5 mg up to max 4 mg QD
No taper is necessary to DC |
|
|
Term
Ropinirole HCl
Pharmacology/Pharmacokinetics |
|
Definition
| Non-ergoline DA agonist w/ full intrinsic activity at the D2 and D3 DA receptor subtypes |
|
|
Term
Ropinirole HCl
Drug Interactions |
|
Definition
1. Cigarette decreases AUC by 38%
2. Omeprazole decreases plasma
3. Cipro increases AUC by 84%
4. Fluvoxamine, mexiletine, & estrogens increase plasma
5. DA antagonists (phenothiazines, butyrophenones, thioxanthenes) may decrease effects |
|
|
Term
Ropinirole HCl
CIs/Precautions |
|
Definition
All Precautions
1. Sudden initiation sleep
2. Syncope
3. Postural hypotension
4. Inhibits PRL secretion and lactation |
|
|
Term
|
Definition
| N, dizziness, somnolence, syncope |
|
|
Term
Ropinirole HCl
Pt consultation |
|
Definition
1. dizziness & drowsiness
2. orthostatic hypotension
3. hallucinations
4. Avoid OH and CNS depressants (OTCs)
5. Smoking cessation
6. If for PD, do not DC abruptly |
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
Metaxalone
FDA indications/Dosages |
|
Definition
Adjunct to rest, physical therapy, & other measures for the reief of discomforts associated w/ acute, painful musculoskeletal conditions
800 mg TID-QID |
|
|
Term
Metaxalone
Pharmacology/Pharmacokinetics |
|
Definition
|
|
Term
Metaxalone
Drug Interactions |
|
Definition
|
|
Term
Metaxalone
CIs/Precautions |
|
Definition
CIs
1. Known tendency to drug induced, hemolytic, or other anemias
2. Renal and liver impairment |
|
|
Term
|
Definition
| N, V, GI discomfort, drowsiness |
|
|
Term
Metaxalone
Pt consultation |
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
| Capsules: 7.5, 15, 22.5, and 30 mg |
|
|
Term
Temazepam
FDA indications/Dosages |
|
Definition
1. Short-term tx of insomnia
7.5-30 mg prior to bedtime. Do not use >10 days
NOT RECOMMENDED FOR CHILDREN <18 Y/O |
|
|
Term
Temazepam
Pharmacology/Pharmacokinetics |
|
Definition
|
|
Term
Temazepam
Drug Interactions |
|
Definition
|
|
Term
|
Definition
CIs
1. hypersensitive to benzo
2. pregnancy |
|
|
Term
|
Definition
| drowsiness, dizziness, lethargy, confusion, euphoria |
|
|
Term
|
Definition
1. Drowsiness
2. Avoid OH
3. habit-forming
4. do not use it > 10 days |
|
|
Term
Dicyclomine HCl
Brand Name |
|
Definition
|
|
Term
Dicyclomine HCl
Dosage Forms |
|
Definition
Capsules: 10 mg
Tablets: 20 mg
Syrup: 10 mg/5 mL
Injection: 10 mg/mL |
|
|
Term
Dicyclomine HCl
FDA indications/Dosages |
|
Definition
IBS: 10-20 mg TID-QID 30 min before meals
IM: 20 mg QID |
|
|
Term
Dicyclomine HCl
Pharmacology/Pharmacokinetics |
|
Definition
| Inhibition of acetylcholine at postganglionic parasympathetic receptor sites |
|
|
Term
Dicyclomine HCl
Drug Interactions |
|
Definition
| Decrease the actions of phenothiazines and haloperidol |
|
|
Term
Dicyclomine HCl
CIs/Precautions |
|
Definition
CIs:
1. UT or intestinal obstruction
2. intestinal atony
3. unstable CV status in acute hemorrhage
4. myasthenia gravis
5. severe ulcerative colitis
6. paralytic ileus
7. glaucoma
8. <6 months of age |
|
|
Term
|
Definition
| Dizziness, HA, N, V, dry mouth |
|
|
Term
Dicyclomine HCl
Pt consultation |
|
Definition
1. Dizziness or drowsiness
2. Avoid OH
3. Dry mouth or difficult urination |
|
|
Term
Hydroxyzine Pamoate
Brand Name |
|
Definition
|
|
Term
Hydroxyzine Pamoate
Dosage Forms |
|
Definition
|
|
Term
Hydroxyzine Pamoate
FDA indications/Dosages |
|
Definition
1. Anxiety & tension associated w/ psychoneurosis and as an adjunct in organic disease states in which anxiety is manifested:
Adults: 50-100 mg QID
>6 y/o: 50-100 mg/day in divided doses
<6 y/o: 50 mg in divided doses
2. Allergy
Adults: 25 mg TID-QID
<6 y/o: 50 mg in divided doses
3. Sedative:
Adults: 50-100 mg
Children: 0.6 mg/kg |
|
|
Term
Hydroxyzine Pamoate
Pharmacology/Pharmacokinetics |
|
Definition
|
|
Term
Hydroxyzine Pamoate
Drug Interactions |
|
Definition
| Potentiate the effects of opiods and barbiturates |
|
|
Term
Hydroxyzine Pamoate
CIs/Precautions |
|
Definition
CIs:
1. hypersensitivity
2. nursing mothers |
|
|
Term
|
Definition
|
|
Term
Hydroxyzine Pamoate
Pt consultation |
|
Definition
|
|
Term
Phenytoin Na (extended)
Brand Name |
|
Definition
|
|
Term
Phenytoin Na (extended)
Dosage Forms |
|
Definition
Capsules: 30 & 100 mg
It is available in IR and injectable |
|
|
Term
Phenytoin Na (extended)
FDA indications/Dosages |
|
Definition
Tonic-clonic & pyschomotor seizures and prevention & tx of seizures occuring during or following neurosurgery
Adult: 100 mg TID; once controlled, switch to once-a-day dosing using the same total dose
Adult LD: 400 mg, 300 mg, and another 300 mg at 2-h intervals
Normal maintenance dosage 24h following LD
Pediatric initial dose: 5 mg/kg/day in 2-3 equally divided doses, may increased up to 300 mg/day
Maintenance dose: 4-8 mg/kg/day; >6 y/o may need 300 mg/day |
|
|
Term
Phenytoin Na (extended)
Pharmacology/Pharmacokinetics |
|
Definition
| increases the extrusion of Na ions from neurons and cardiac myocytes |
|
|
Term
Phenytoin Na (extended)
Drug Interactions |
|
Definition
|
|
Term
Phenytoin Na (extended)
CIs/Precautions |
|
Definition
|
|
Term
Phenytoin Na (extended)
ADEs |
|
Definition
| Nystagmus, ATAXIA, SLURRED SPEECH, MENTAL CONFUSION |
|
|
Term
Phenytoin Na (extended)
Pt consultation |
|
Definition
1. Take with food
2. Drowsiness
3. Practice good oral hygiene
4. Contact MD if rash or using nonRx
5. Monitor glucose if diabetics |
|
|
Term
Valsartan w/ HCTZ
Brand Name |
|
Definition
|
|
Term
Valsartan w/ HCTZ
Dosage Forms |
|
Definition
| Tablets: 80/12.5, 160/12.5, 160/25, 320/12.5, 320/25 |
|
|
Term
Valsartan w/ HCTZ
FDA indications/Dosages |
|
Definition
HTN
Starting dose: 80 mg
Max dose: 320 mg
Normal dosage is 1 tab daily |
|
|
Term
Valsartan w/HCTZ
Pharmacology/Pharmacokinetics |
|
Definition
Valsartan blocks Ang II
HCTZ inhibits reabsorption of Na & Cl at DCT |
|
|
Term
Valsartan w/ HCTZ
Drug Interactions |
|
Definition
1. HCTZ may decrease sulfonylurea hypoglycemia
2. Digitalis-induced arrhythmias
3. HCTZ + diazoxide may cause hyperglycemia
4. HCTZ increase Li levels
5. NSAIDs decrease effects and increase risk of renal fx |
|
|
Term
Valsartan w/ HCTZ
CIs/Precautions |
|
Definition
CIs
1. anuria
2. hypersensitivity to sulfonamide-derived drugs
3. DC if pregnant |
|
|
Term
|
Definition
| dizziness, viral infection, fatigue, phargynitis |
|
|
Term
Valsartan w/ HCTZ
Pt consultation |
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
Tablets: 50, 100, 150, and 200 mg
Powder for oral suspension: 10 & 40 mg/mL
Injection: 2 mg/mL |
|
|
Term
Fluconazole
FDA indications/Dosages |
|
Definition
1. vaginal candidiasis
2. oropharyngeal candidiasis
3. esophageal candidiasis
4. systemic candidiasis
5. cryptococcal meningitis
6. Renal impairment
7. Regula hemodialysis
8 Children's dosing |
|
|
Term
Fluconazole
Pharmacology/Pharmacokinetics |
|
Definition
| inhibits 14 alpha demethylation |
|
|
Term
Fluconazole
Drug Interactions |
|
Definition
1. Prothrombin time is increased w/ Warfarin
2. Incrases plasma levels of phenytoin, midazolam, and cyclosporine
3. increases the pasma [ ]s & reduces the metabolism of tolbutamide, glycuride, and glipizide
4. Rifampin increases fluconazole |
|
|
Term
Fluconazole
CIs/Precautions |
|
Definition
CIs:
1. hypersensitivity
2. nursing mothers |
|
|
Term
|
Definition
| N, HA, abd pain, D, dizziness |
|
|
Term
Fluconazole
Pt consultation |
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
NPH (N)
Regular (R)
70/30
50/50 |
|
|
Term
Insulin
FDA indications/Dosages |
|
Definition
|
|
Term
Insulin
Pharmacology/Pharmacokinetics |
|
Definition
| proper glucose utilization in metabolic processes-promotes the transport of monosaccharides across cell membranes and facilitates the transformation of intracellular aas into ptns |
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
| Hypoglycemic, hpersensitivity |
|
|
Term
|
Definition
|
|
Term
Fluticasone Propionate MDI
Brand Name |
|
Definition
|
|
Term
Fluticasone Propionate MDI
Dosage Forms |
|
Definition
| Each actuation 44 mcg (60), 110 mcg (120), 220 mcg (120) |
|
|
Term
Fluticasone Propionate MDI
FDA indications/Dosages |
|
Definition
1. Maintenance tx of asthma as prophylactic therapy
2. 4-11 y/o:
3. Pts receiving systemic steroids |
|
|
Term
Fluticasone Propionate MDI
Pharmacology/Pharmacokinetics |
|
Definition
|
|
Term
Fluticasone Propionate MDI
Drug Interactions |
|
Definition
|
|
Term
Fluticasone Propionate MDI
CIs/Precautions |
|
Definition
|
|
Term
Fluticasone Propionate MDI
ADEs |
|
Definition
|
|
Term
Fluticasone Propionate MDI
Pt consultation |
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
| Pharmacology/Pharmacokinetics |
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
| Pharmacology/Pharmacokinetics |
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
| Pharmacology/Pharmacokinetics |
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
| Pharmacology/Pharmacokinetics |
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
| Pharmacology/Pharmacokinetics |
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
| Pharmacology/Pharmacokinetics |
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
| Pharmacology/Pharmacokinetics |
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
| Pharmacology/Pharmacokinetics |
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
| Pharmacology/Pharmacokinetics |
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
| Pharmacology/Pharmacokinetics |
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
